2025年10月27日 / 最終更新日 : 2025年10月27日 ad_y ニュース

2025年 新着論文 46　糖尿病診療分野から論文が発表されました

Consensus statement on novel glucose-related metrics obtained through advanced medical devices: English version

Diabetol Int. 2025 Jun 18;16(4):595-613. doi: 10.1007/s13340-025-00820-2. eCollection 2025 Oct.

Authors

Rimei Nishimura #  1 , Yosuke Okada  2 , Akio Kuroda #  3 , Junichi Suzuki #  4 , Yushi Hirota #  5 , Munehide Matsuhisa #  3 , Mizuki Ishiguro #  1 , Takayuki Ohno #  1 , Yuka Suganuma #  1 , Kenichi Tanaka #  2 , Atsuhito Tone #  6 , Akane Yamamoto #  5 , Sumiko Yoshida #  7

Affiliations

  • 1 Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461 Japan.
  • 2 First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555 Japan.
  • 3 Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503 Japan.
  • 4 Department of Pediatrics, Nihon University School of Medicine, 30-1 Oyaguchi-kami-cho, itabashi-ku, Tokyo, 173-8610 Japan.
  • 5 Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017 Japan.
  • 6 Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital, 2-25 Kokutai-cho, Kita-ku, Okayama, Okayama 700-8511 Japan.
  • 7 Department of Clinical Research, Shikoku Medical Center for Children and Adults, 2-1-1 Sen-yu-cho, Zentsuji, Kagawa 765-8507 Japan.
# Contributed equally.
No abstract available

Keywords: Continuous glucose monitoring; Glucose control goal; Glucose target; Glycemic excursion; Glycemic variability [GV]; Time in range (TIR).

Conflict of interest statement

Conflict of interestRimei Nishimura: lecture fees (Sanofi K.K., Medtronic, Nippon Boehringer Ingelheim Co., Ltd., Teijin Pharma Ltd., Kissei Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Astellas Pharma Inc., Abbott Japan, Sumitomo Pharma Co., Ltd., AstraZeneca, Kowa Co., Ltd., and Ono Pharmaceutical Co., Ltd.); research funds and grants (Mitsubishi Electric Corporation); endowments (scholarships) and donations (Taisho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Abbott Japan, and Sumitomo Pharma Co., Ltd.). Yosuke Okada: lecture fees (MSD, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Kowa Co., Ltd., and Sumitomo Pharma Co., Ltd.); research funds and grants (Kissei Pharmaceutical Co., Ltd.). Akio Kuroda: lecture fees (Eli Lilly Japan K.K.). Yushi Hirota: lecture fees (Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Sanofi K.K., Terumo Corporation, Sumitomo Pharma Co., Ltd., and Abbott Japan); research funds and grants (Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Kyowa Kirin Co., Ltd., and Medtronic); endowments (scholarships) and donations (Abbott Japan). Munehide Matsuhisa: lecture fees (Abbott Japan, Sanofi K.K., Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Kyowa Kirin Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.); research funds and grants (Japan Association for Diabetes Education and Care). Atsuhito Tone: lecture fees (Sanofi K.K., Eli Lilly Japan K.K., Abbott Japan, and Terumo Corporation).

Full text links

カテゴリー
ニュース